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We have constructed on the cDNA level deletion mutants of human interleukin-6 lacking one, two, three or four amino acids from the carboxy- 
terminus of the molecule. After in vitro transcription and translation the biological activity of these deletion mutants was determined by two inde- 
pendent bioassays. Both, the mouse B9 cell proliferation assay and the fibrinogen induction assay with the human hepatoma cell line HepG2 led 
to the following result: already the removal of the last amino acid resulted in a five-fold loss of biological activity. An additional slight reduction 
was seen when two amino acids were removed from the carboxy-terminus. Interleukin-6 lacking three or four C-terminal amino acids were complete- 
ly inactive. The presented results emphasize the extreme importance of the carboxy-terminus of interleukin-6 for its biological function. 
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1. INTRODUCTION 
Interleukind (IL-6) is produced and secreted by 
many different cell types, particularly by those of the 
immune system. It elicits a wide spectrum of biological 
functions. In general, IL-6 acts as a growth and dif- 
ferentiation factor on B-cells, T-cells, lymphoma cells, 
hybridoma/plasmacytoma cells, hematopoietic stem 
cells, and hepatocytes (for reviews see [1,2]). More 
recently the involvement of IL-6 in the oncogenesis of 
plasma cell neoplasias has been discussed [3]. 
IL-6 consists of 184 amino acids [4]. It is synthesized 
as a larger polypeptide precursor with a signal peptide 
of 28 amino acids. IL-6 exerts its action via a specific 
receptor on the surface of various target cells [5]. A 
human ILd-receptor-cDNA has recently been cloned 
from natural killer cells [6]. In order to understand the 
interaction of IL-6 with its receptor it is important to 
obtain some information on structural features essen- 
tial for its biological function. Recently we have con- 
structed a whole set of C-terminal truncations of the 
IL-6 protein and could show that the removal of only 
four amino acids is sufficient to completely abrogate its 
biological activity [7]. 
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In the present study we present evidence that residues 
182 and 184 are of particular importance for the 
biological function of IL-6. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
L-[3sS]methionine (> 37 TBq/mmol), 6-[‘Hlthymidine (74 
GBq/mmol) and [cx-~~S]~ATP (37 TBq/mmol) were purchased from 
Amersham International (Amersham, UK). All enzymes were obtain- 
ed from Boehringer (Mannheim, FRG). Anti-human fibrinogen was 
obtained from Dako (Hamburg, FRG). Human IL-6-cDNA and 
rhIL-6 [8] were a generous gift of Drs T. Hirano and T. Kishimoto 
(Osaka, Japan); rhIL-6 had a specific activity of 6 x lo8 units/mg pro- 
tein (B9 cell proliferation assay). 
2.2. Construction of IL-6 deletion mutants 
IL-6 deletion mutants were constructed using PCR techniques 191. 
IL-6-cDNA in pGEM4 [4] was amplified by PCR using one primer at 
the 5 ‘-end (5 ‘TTG TAC ATA TTG TCG TT 3 ‘) and 3 different 
primers at the 3’-end (S’TCT AGA ATT CTA TTG CCG AAG AGC 
CCT CAG 3 ’ ; 5 ’ TCT AGA ATT CTA CCG AAG AGC CCT CAG 
GCT 3 ’ ; 5 ’ TCT AGA ATT CTA AAG AGC CCT CAG GCT GGA 
3’). The obtained IL-6-cDNAs lacked the 3’-non-coding region and 
contained the translational stop codon TAG after leucine, arginine 
and glutamine, at positions 181, 182 and 183, respectively. PCR was 
carried out using 10 ng of plasmid DNA and 200 ng of each primer 
(annealing, 42°C 120 s; synthesis, 72”C, 180 s; denaturation, 94”C, 
90 s; 35 cycles). PCR products were digested with EcoRl and cloned 
into the transcription vector pGEM3. All constructs were verified by 
DNA sequencing. The construction of the IL-6-cDNA lacking the last 
12 nucleotides of the coding region (A 4) has been recently described 
[7]. The linearized plasmids were transcribed with T7 RNA 
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polymerase and subsequently translated in a cell-free system (rabbit 
reticulocyte iysate) in the presence of [35S]methionine ]lO]. After 
SDS-PAGE of the cell-free synthesized polypeptides IL-6 bands were 
excised from the polyacrylamide gel and their radioactivity was deter- 
mined. The values were normalized taking into account he number of 
methionine residues present in full length IL-6 and deletion mutants. 
2.3. B9 cell proliferation assay 
The IL-6 assay was carried out with the IL-ddependent murine 
plasmacytoma cell line B9 kindly provided by L. Aarden (Amster- 
dam, The Netherlands) [I 11. One ~1 of the translation mixture and 
serial dilutions (1:2) were used in the B9 cell proliferation assay. 
2.4. Fibrinogen induction assay 
IL-6 activity was measured by ~brinogen induction in human 
HepG2 cells 1121. i@ ceils were incubated in a total volume of 300 ~1 
medium with serial dilutions (1:2) of cell-free synthesized full length 
IL-6 and deletion mutants. After 18 h the medium was removed and 
replaced by medium containing 167 kBq [3sS]methionine. 4 h later, 
newly synthesized and secreted radiolabeled fibrinogen was im- 
munoprecipitated, separated by SDS-PAGE and subjected to 
fluorography [ 131. 
Since the reticulocyte lysate at higher concentrations interferes with 
both IL-6 assays, we always used equal and subtoxic amounts of 
translation mixtures to evaluate the biological activity of the IL-6 
mutants. 
3. RESULTS AND DISCUSSION 
Previous results had demonstrated the crucial role of 
the C-terminus of IL-6 for its biological activity [7]. 
Already the elimination of the 4 carboxy-terminal 
amino acid residues led to a complete loss of activity 
[7]. For a more detailed analysis of this finding we have 
now synthesized eletion mutants of IL-6 lacking 1,2, 
or 3 amino acids of the C-terminal end of the polypep- 
tide. These mutants constructed by PCR technology 
were cell-free transcribed and subsequently translated 
into proteins using a reticulocyte lysate. As shown in 
Fig. 1 aliquots of the translation mixtures were 
separated by SDS-PAGE. A slight increase in elec- 
trophoretic mobility can be observed when the deletions 
are compared to the full length IL-6 (AO). 
In Fig. 2 we show the IL-6 dependent proliferation of 
B9 cells as measured by [3H]thymidine uptake. A dose- 
dependent proliferation of B9 cells is detected, when 
full length IL-6 (AO) is added to the cells. No cell 
growth is observed without IL-6 addition (‘no IL-6’). 
The removal of the last amino acid (compare Fig. 5) led 
to a signifi~nt decrease in the biologic~ activity of this 
IL-6 mutant. A further slight reduction was observed 
for an IL-6 polypeptide lacking 2 amino acids of its 
carboxy-terminus. Elimination of a third amino acid 
completely abolished IL-6 activity (Fig. 2). As controls 
we used rhIL-6 in concentrations, which gave a com- 
plete response profile in the B9 proliferation assay (co 
A). Addition of one ,ul of reticulocyte lysate did not 
change the activity of the IL-6 standard (co B). 
In the experiments described above we used murine 
plasmacytoma cells (B9) to measure the biological ac- 
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Fig. I. SDS-PAGE of cell-free synthesized IL-6 mutants deleted at the 
carboxy-te~inus. Full length IL-6 and deleted forms obtained after 
in vitro transcription and translation were separated by SDS- 
polyacrylamide gel (12.5%) dectrophoresis and visualized by 
fluorography (131. A0 represents the full length IL-6 control; A 1, 
A2, A3, A4 denote the IL-6 polypeptides lacking 1, 2, 3, 4 amino 
acids from the carboxy-terminus, respectively. 
tivity of human IL-6. Therefore, we chose to verify our 
results in a homologous system using the fibrinogen in- 
duction assay with human hepatoma cells (HepG2) 
[12]. These results are shown in Fig. 3. Full length IL-6 
induced the synthesis of all three fibrinogen polypeptide 
chains in a dose-dependent manner. Again, removal of 
one or two amino acids resulted in a substantial reduc- 
tion of biological activity, whereas truncation of 3 
amino acid residues led to a completely inactive IL-6 
molecule. In both assay systems mutants lacking 4 
carboxy-terminal amino acids were inactive, too. Con- 
trols were the same as described for Fig. 2. Fig. 4 shows 
a comparison of data obtained in the B9 proliferation 
and the fibrinogen induction test. The fact that major 
decreases in IL-6 activity occur upon deletion of 
Met-184 (Al) and Arg-182 (A2) indicates the par- 
ticular importance of these residues. It should be noted 
that the effect of the respective mutations is the same in 
the murine and the human assay system. This is 
especially interesting in view of the fact that murine 
IL-6 only binds to the murine IL-6-receptor, whereas 
human IL-6 recognizes both, the human and murine 
receptor [ 141, pointing to important structural dif- 
ferences between the two receptors and ligands. 
Having shown the importance of the carboxy- 
terminus of IL-6 for its function, we examined the 
possibility that a synthetic peptide, consisting of the 15 
carboxy-ter~nal amino acids of mouse IL-6 [ 151, could 
exert IL-6 activity. This peptide had neither an in- 
hibitory nor stimulatory effect on the proliferation of 
B9 cells if compared to rhIL-6 (data not shown). 
We find it puzzling that the last amino acid, which 
seems to be important for function is not conserved bet- 
ween mouse and man (Fig. 5). Site-directed mutagenesis 
studies of the carboxy-terminus of IL-6 will be needed 
to define the precise structural requirements of this part 
of the molecule for biological activity. 
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Fig. 2. Growth factor activity of full length and carboxy-terminally deleted IL-6 polypeptides. Aliquots of the translation cocktails containing com- 
parable amounts of cell-free synthesized IL-6 were used in the I39 cell proliferation assay as measured by 13H~th~dine uptake. ‘co A’ represents 
the dilution of a rhIL-6 standard (activity of the first dilution: 20 U/ml), ‘co B’ is identical to ‘co A’ except for the addition of 1 _td of a mock 
translation mixture; ‘no IL-6’ represents a control, where proliferation of unstimulated B9 cells was measured. 
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Fig. 3. Fibrinogen induction of full length and carboxy-terminally 
deleted IL-6 polypeptides. 15 pl aliquots and serial dilutions (1:2) of 
the translation mixtures were used to induce fibrinogen secretion in 
HepG2 cells. Immunoprecipitated cr-, p- and -r-fibrinogen was 
counted and separated on 10% SDS-PAA-gels and subjected to 
fluorography. ‘co A’ is the dilution of rhIL-6 (330 U/ml), ‘co B’ is the 
same as ‘co A’ except for the addition of 15 ~1 of a mock translation 
mixture; ‘no IL-6’ represents acontrol, where fibrinogen secretion of 
unstimulated HepG2 cells was measured. 
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Fig. 4. Comparison of the biological activity of IL-6 mutants as 
measured in the B9 and HepG2 cell assay. Values, normalized for dif- 
ferent amounts of IL-6 synthesized, were compared using the dilution 
leading to half-maximal stimulation in the respective test. The 
biological activity exerted by full-length IL-6 (AO) was set to 100%. 
Open bars: B9 cell proliferation assay, average of 3 determinations; 
hatched bars; HepG2 cell fibrinogen assay, average of 2 determina- 
tions. 
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Fig. 5. Sequence comparison of the carboxy-terminus of human and 
murine IL-6. 
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